我要投票 以岭药业在中草药行业中的票数:441
· 外 推 电 报 ·
2025-08-06 08:19:28 星期三

【以岭药业是哪个国家的品牌?】

以岭药业是什么牌子?「以岭药业」是 石家庄以岭药业股份有限公司 旗下著名品牌。该品牌发源于河北,由创始人吴相君在2001期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力以岭药业品牌出海!将品牌入驻外推网,定制以岭药业品牌推广信息,可以显著提高以岭药业产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

国家重点高新技术企业--石家庄以岭药业股份有限公司由中国工程院吴以岭院士创建,在他的领导下,以岭药业始终坚持以科技为先导,以市场为龙头的科技创新发展战略,创立"理论-科研-新药-生产-营销"五位一体的独特运营模式,建立起以中医络病理论创新为指导的新药研发创新技术体系。

在以岭药业的发展历程中,凝聚了一大批科研、管理、生产、营销精英,包括归国专家、外籍专家、博士、硕士及各类高职人才,为河北医科大学培养博士、硕士研究生,被国家人事部批准为博士后科研工作站。

以岭药业以络病理论创新带动中医药产业化,运用现代高新技术研发现代中药、西药、和生物药,研发国家专利新药9个,覆盖心脑血管疾病、感冒呼吸疾病、肿瘤、糖尿病及其并发症等重大疾病领域。通过国家GMP认证的中药生产线、通过欧盟认证的化学制剂生产车间具有年产值达50亿的生产能力。以岭药业为国家创新型企业、中国制药工业50强,以岭商标成为中国驰名商标。

国家科技部前领导曾赞誉五位一体的发展模式为"我国中医药科技成果产业化的创举"。

以岭药业立足国内、接轨国际,在石家庄、北京大兴、密云建立了三个国际标准的科研生产基地,通过了欧盟、新西兰等GMP认证。科研、生产、质检、贸易、管理人才全部具有国际化背景,构建了符合国际药品标准的生产、质控体系。依靠现代高新技术与设备和完善的药品生产质量控制体系,生产高品质中药与西药。产品已经出口到英国、美国、西班牙、韩国、日本、俄罗斯、新西兰等许多国家。

位于北京生物工程与医药产业基地的北京以岭药业,占地210亩,为国家重点高新技术企业,主要生产面向国际市场的植物药、保健品、膳食补充剂。

位于北京密云的北京以岭生物按照欧美GMP标准建设,主要生产面向国际市场的激素、肿瘤类药物和具有自主知识产权的新制剂。

英文翻译:Shijiazhuang Yiling Pharmaceutical Co., Ltd, a national key high-tech enterprise, was founded by Academician Wu Yiling of Chinese Academy of engineering. Under his leadership, Yiling pharmaceutical always adheres to the development strategy of scientific and technological innovation with science and technology as the guide and market as the leader, creates a unique operation mode of "theory research new medicine production marketing" and establishes a theoretical innovation of traditional Chinese medicine collateral disease as the reference New drug R & D innovation technology system. In the development process of Yiling pharmaceutical industry, a large number of scientific research, management, production and marketing elites, including returned experts, foreign experts, doctors, masters and all kinds of higher vocational talents, have been gathered, training doctors and masters for Hebei Medical University, and approved by the Ministry of human resources as post doctoral research workstation. Lingyao promotes the industrialization of traditional Chinese medicine with the innovation of collateral disease theory, develops modern Chinese medicine, western medicine and biological medicine with modern high and new technology, and develops 9 new national patent drugs, covering the major disease fields such as cardio cerebrovascular disease, cold and respiratory disease, tumor, diabetes and its complications. The production line of traditional Chinese medicine certified by national GMP and the chemical production workshop certified by European Union have an annual output value of 5 billion. Take Ling pharmaceutical as a national innovative enterprise and top 50 pharmaceutical industry in China, and take Ling trademark as a well-known trademark in China. Former leaders of the Ministry of science and technology of the people's Republic of China once praised the five in one development mode as "the pioneering work of industrialization of scientific and technological achievements of traditional Chinese medicine". Based on domestic and international standards, Yiling pharmaceutical has established three international standard research and production bases in Shijiazhuang, Beijing Daxing and Miyun, and has passed GMP certification of EU, New Zealand, etc. The talents of scientific research, production, quality inspection, trade and management all have international background, and the production and quality control system in line with international drug standards has been established. Relying on modern high-tech and equipment and perfect quality control system of drug production, we can produce high-quality traditional Chinese medicine and Western medicine. The products have been exported to the United Kingdom, the United States, Spain, South Korea, Japan, Russia, New Zealand and many other countries. Located in Beijing bioengineering and pharmaceutical industry base, Beijing Yiling pharmaceutical, covering an area of 210 mu, is a national key high-tech enterprise, which mainly produces plant medicine, health care products and dietary supplements for the international market. Beijing Yiling biology, located in Miyun, Beijing, is built in accordance with European and American GMP standards. It mainly produces hormones, tumor drugs and new preparations with independent intellectual property rights for the international market.

本文链接: https://www.waitui.com/brand/887854f10.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

世界机器人大会即将开幕,十八只概念股半年报业绩向好

8月8日,2025世界机器人大会将在北京经济技术开发区北人亦创国际会展中心启幕。据了解,将有100余款新品在大会上首发亮相,数量是去年的近2倍。据统计,目前布局人形机器人产业链的概念股多达120只。截至8月5日,已公布2025年半年报业绩数据的概念股中,净利润同比增长20%及以上或扭亏为盈(业绩预告取下限数据)的有18股,其中,天奇股份、麦迪科技、埃斯顿、中京电子、爱仕达等预计扭亏为盈。(证券时报)

20分钟前

国泰海通:钢铁盈利率持续回升,继续看好板块布局机会

36氪获悉,国泰海通发布研报称,需求有望逐步触底,供给端即便不考虑供给政策,目前钢铁行业亏损时间已经较长,供给的市场化出清已开始出现,预期钢铁行业正在逐步走出底部。而若供给政策落地,行业供给的收缩速度更快,行业上行的进展将更快展开。

20分钟前

中缅签署2025年澜湄合作专项基金项目合作协议

2025年澜湄合作专项基金项目合作协议签约仪式5日在缅甸首都内比都举行。中国驻缅甸大使马珈与缅外交部副部长戈戈觉签署协议。马珈在签约仪式上致辞表示,此次签约的14个项目将继续支持缅甸农业、环保、科技、文化、教育和防灾等多领域发展。中方愿同缅方加强合作,把基金用好,推动中缅命运共同体建设为两国人民带来更多福祉。缅甸国家安全与和平委员会成员、外交部长丹穗在致辞中表示,缅甸政府和人民真诚感谢中方出资设立基金,与缅分享发展机遇。(新华社)

20分钟前

巴西将美加征关税行为诉至世贸争端解决机制

当地时间8月5日,巴西总统卢拉在外交部出席一场会议时表示,美国总统无权对巴西加征50%的高额关税。巴西将启动应急计划,以减轻这一不公正行为带来的冲击,尽量减少经济和社会损失。卢拉表示,巴西政府将保护受影响的工人和企业,动用一切可用手段,首先是向世界贸易组织提出申诉,以捍卫国家利益。卢拉还表示,当天联邦政府发布的一项决议已授权外交部将美方行为诉至世贸组织争端解决机制,以应对美国的关税上调。(央视新闻)

20分钟前

Sam Altman再度预热GPT 5:比最聪明的人还要聪明

OpenAI CEO Sam Altman在社交媒体平台“X”上发文称:“不久的将来,一种比你认识的最聪明的人还要聪明的人工智能将会运行在你口袋里的设备上,帮助你完成任何你想做的事情。这是一件非常了不起的事情。”近日多家媒体报道,OpenAI下一代旗舰模型GPT-5即将发布,OpenAI高管也频繁在社媒上释放相关信号。(新浪财经)

20分钟前

本页详细列出关于以岭药业的品牌信息,含品牌所属公司介绍,以岭药业所处行业的品牌地位及优势。
咨询